Company: SCLXW
Filing Date: 2025-08-21
Form Type: 424B3
Source: 0001193125-25-184630
Chunk: 1

Company: Scilex Holding Co
Filing Date: 2025-08-21
Form: 424B3
Chunk 1
---
 supplement is being filed to update and supplement the information in the Prospectuses with the information contained in our Current Report on Form 8-K,filed with the SEC on August 21, 2025 (the “Report”). Accordingly, we have attached the Report to this prospectus supplement. Our Common Stock is listed on the Nasdaq Capital Market under the symbol “SCLX”. On August 20, 2025, the last reported sales price per share of our Common Stock was $17.57. Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On August 20, 2025, the closing sale price per warrant of our Public Warrants was $0.53. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35(the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect of the Reverse Stock Split. This prospectus supplement updates and supplements the information in the Prospectuses and is not complete without, and may not be delivered or utilized except in combination with, the Prospectuses, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectuses and if there is any inconsistency between the information in the Prospectuses and this prospectus supplement, you should rely on the information in this prospectus supplement. See the section titled “Risk Factors” beginning on page 23 of the Post-deSPAC Prospectus, page 23 of the Conversion Prospectus, and page 23 of the Oramed Resale Prospectus, as well as risks and uncertainties described under similar headings in any amendments or supplements to the Prospectuses to read about factors you should consider before buying our securities. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement or the Prospectuses. Any representation to the contrary is a criminal offense. The date of this prospectus supplement is August 21, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 16, 2025 SCILEX HOLDING COMPANY (Exact